Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other selected tumors.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513379-41-00

Acronym

CDFF332A12101

Enrollment

Registered

2024-06-11

Start date

2021-01-26

Completion date

2024-11-25

Last updated

2024-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced, relapsed Clear Cell Renal Cell Carcinoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Czechia, France, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026